Alan Schwartz, MD
Pulmonary Disease · Baltimore, MDNPI 1639194392
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $991,064 of the $1,273,229 with a category attached, or 77.8%. 45 manufacturers reported payments, led by Itamar Medical Inc at 54.5% of the total. Among pulmonary disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $3546.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Itamar Medical Inc$694K
- Livanova USA, Inc.$281K
- ZOLL Respicardia, Inc.$261K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Philips North America LLC$5K
- Jazz Pharmaceuticals Inc.$5K
- plus $9K from 39 others
Across 33 payments — averaging $10,997 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Itamar Medical Inc$173K
- Philips North America LLC$137K
- Livanova USA, Inc.$54K
What the payments were for
- Consulting fees$991,06478%
- Speaking & faculty fees$257,10620%
- Travel & lodging$16,2261%
- Food & beverage$8,8091%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WatchPat$455,708
- THN Sleep Therapy$278,077
- remede System$261,075
- WatchPATONE$238,756
- IGT D Peripheral$4,620
- VNS Therapy$2,437
- AIR 11$1,200
- Inspire$273
- SUNOSI$125
- TRELEGY ELLIPTA$123
How this compares
$1,273,229 in reported general payments places this provider in the 95th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 15 | $128 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Baltimore
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
- Jason AkulianBaltimore$231K
- Kathryn RobinettBaltimore$160K
- Sonye DanoffBaltimore$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.